Literature DB >> 7767950

The absorption of 6-mercaptopurine from 6-mercaptopurine riboside in rat small intestine: effect of phosphate.

A M Pennington1, J R Bronk.   

Abstract

The intestinal absorption of 6-mercaptopurine and its nucleoside 6-mercaptopurine riboside has been studied in the rat with the in situ dual luminal and vascular perfusion. 6-Mercaptopurine is an inactive prodrug that requires intestinal absorption, cellular uptake and intracellular anabolism for cytotoxic activity. Vascular and mucosal samples were analysed by high-performance liquid chromatography (HPLC) to assess the rate of vascular appearance and amounts of thiopurine and its nucleoside in the mucosa. With 5 mmol luminal 6-mercaptopurine/l, the drug is transported across the intestine unchanged at a rate of 0.053 +/- 0.006 mumol min-1 (g dry wt.)-1. At concentrations below 20 mmol/l, 6-mercaptopurine riboside is not transported across the intestine intact but is split by phosphorolysis in the intestinal mucosa. The rate of vascular appearance of 6-mercaptopurine [0.043 +/- 0.005 mumol min-1 (g dry wt.)-1] from 5 mmol luminal 6-mercaptopurine riboside/l did not differ significantly from that seen with 5 mmol luminal 6-mercaptopurine/l. When the lumen was perfused with 6-mercaptopurine riboside the riboside appeared in the tissue together with a higher mucosal concentration of 6-mercaptopurine than in perfusions with 6-mercaptopurine. Some metabolism of 6-mercaptopurine to 6-thioguanine was also observed; however, no 6-thioguanine appeared in the vascular effluent. Increasing the luminal phosphate concentration from 2 to 10 mmol/l increased mucosal phosphorolysis of 6-mercaptopurine riboside and more than tripled the rate of vascular appearance of 6-mercaptopurine; conversion of 6-mercaptopurine to 6-thioguanine was significantly inhibited. These results suggest that with a modest increase in luminal phosphate concentration, 6-mercaptopurine riboside can be a more effective substrate than the free drug for the oral delivery of 6-mercaptopurine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7767950     DOI: 10.1007/BF00689198

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  The utilization of glucose and production of lactate by in vitro preparations of rat small intestine: effects of vascular perfusion.

Authors:  P J Hanson; D S Parsons
Journal:  J Physiol       Date:  1976-03       Impact factor: 5.182

Review 2.  Milestones in the treatment of gout.

Authors:  T Yü; T F Yu
Journal:  Am J Med       Date:  1974-05       Impact factor: 4.965

3.  A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine.

Authors:  D M Tidd; A R Paterson
Journal:  Cancer Res       Date:  1974-04       Impact factor: 12.701

4.  Consequences of inhibition of purine biosynthesis de novo by 6-methylmercaptopurine ribonucleoside in cultured lymphoma L5178Y cells.

Authors:  R A Woods; R M Henderson; J F Henderson
Journal:  Eur J Cancer       Date:  1978-07       Impact factor: 9.162

5.  Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?

Authors:  S Zimm; J M Collins; R Riccardi; D O'Neill; P K Narang; B Chabner; D G Poplack
Journal:  N Engl J Med       Date:  1983-04-28       Impact factor: 91.245

6.  6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts.

Authors:  J P Bökkerink; E H Stet; R A De Abreu; F J Damen; T W Hulscher; M A Bakker; J A van Baal
Journal:  Biochem Pharmacol       Date:  1993-04-06       Impact factor: 5.858

Review 7.  Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia.

Authors:  B Bostrom; G Erdmann
Journal:  Am J Pediatr Hematol Oncol       Date:  1993-02

8.  Purine nucleoside transport and metabolism in isolated rat jejunum.

Authors:  R A Stow; J R Bronk
Journal:  J Physiol       Date:  1993-08       Impact factor: 5.182

9.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.

Authors:  L Lennard; J S Lilleyman; J Van Loon; R M Weinshilboum
Journal:  Lancet       Date:  1990-07-28       Impact factor: 79.321

10.  Transport and metabolism of 6-thioguanine and 6-mercaptopurine in mouse small intestine.

Authors:  J R Bronk; N Lister; M I Shaw
Journal:  Clin Sci (Lond)       Date:  1988-06       Impact factor: 6.124

View more
  2 in total

1.  Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model.

Authors:  Filippos Kesisoglou; Simon Yuji Zhou; Susan Niemiec; Jordan Wing Lee; Ellen M Zimmermann; David Fleisher
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

2.  Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.

Authors:  F Innocenti; R Danesi; A Di Paolo; B Loru; C Favre; M Nardi; G Bocci; D Nardini; P Macchia; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.